These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
300 related articles for article (PubMed ID: 33161728)
1. The Time Is Now for Sodium Glucose Co-Transporter 2 Inhibitors for Heart Failure: A Call to Overcome Clinical Inertia. Khan MS; Butler J; Greene SJ Circ Heart Fail; 2020 Dec; 13(12):e008030. PubMed ID: 33161728 [No Abstract] [Full Text] [Related]
3. The sodium-glucose co-transporter 2 inhibitor dapagliflozin improves prognosis in systolic heart failure independent of the obesity paradox. Carbone S; daSilva-deAbreu A; Lavie CJ Eur J Heart Fail; 2021 Oct; 23(10):1673-1676. PubMed ID: 34427026 [No Abstract] [Full Text] [Related]
4. Empagliflozin in the treatment of heart failure and type 2 diabetes mellitus: Evidence from several large clinical trials. Liang B; Gu N Int J Med Sci; 2022; 19(7):1118-1121. PubMed ID: 35919809 [TBL] [Abstract][Full Text] [Related]
5. Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and uric acid: More good news! Katsiki N; Rizzo M; Mikhailidis DP J Diabetes Complications; 2023 Jul; 37(7):108510. PubMed ID: 37235924 [No Abstract] [Full Text] [Related]
6. Sodium-Glucose Co-Transporter-2 Inhibitors Decrease the Odds for Atrial Fibrillation in Subjects with Heart Failure. Patoulias D; Papadopoulos C; Doumas M J Stroke Cerebrovasc Dis; 2022 Mar; 31(3):106257. PubMed ID: 34953683 [No Abstract] [Full Text] [Related]
7. Resistance to Diuretics in Heart Failure: Any Role for Empagliflozin? Katsiki N; Triposkiadis F Curr Vasc Pharmacol; 2019; 17(4):421-424. PubMed ID: 30173648 [No Abstract] [Full Text] [Related]
8. Sodium glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Tsampasian V; Elghazaly H; Chattopadhyay R; Ali O; Corballis N; Chousou PA; Clark A; Garg P; Vassiliou VS Eur J Prev Cardiol; 2022 May; 29(6):e227-e229. PubMed ID: 34850881 [No Abstract] [Full Text] [Related]
9. Emerging Topics in Heart Failure: Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) in HF. Bocchi EA; Biolo A; Moura LZ; Figueiredo Neto JA; Montenegro CEL; Albuquerque DC Arq Bras Cardiol; 2021 Feb; 116(2):355-358. PubMed ID: 33656089 [No Abstract] [Full Text] [Related]
10. The DAPA-HF trial marks the beginning of a new era in the treatment of heart failure with reduced ejection fraction. Verma S Cardiovasc Res; 2020 Jan; 116(1):e8-e10. PubMed ID: 31850505 [No Abstract] [Full Text] [Related]
11. Dapagliflozin (Farxiga) - a new indication for heart failure. Med Lett Drugs Ther; 2020 Jun; 62(1601):102-103. PubMed ID: 32724023 [No Abstract] [Full Text] [Related]
12. Sodium-glucose co-transporter-2 inhibitors and cardiovascular outcome studies in people with type 2 diabetes: From efficacy to effectiveness. Khunti K; Kosiborod M Diabetes Obes Metab; 2018 Apr; 20(4):763-765. PubMed ID: 29077267 [No Abstract] [Full Text] [Related]